IMNM (Immunome) Retained Earnings : $-435.52 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunome Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Immunome's retained earnings for the quarter that ended in Sep. 2024 was $-435.52 Mil.

Immunome's quarterly retained earnings declined from Mar. 2024 ($-352.30 Mil) to Jun. 2024 ($-388.42 Mil) and declined from Jun. 2024 ($-388.42 Mil) to Sep. 2024 ($-435.52 Mil).

Immunome's annual retained earnings declined from Dec. 2021 ($-79.11 Mil) to Dec. 2022 ($-116.00 Mil) and declined from Dec. 2022 ($-116.00 Mil) to Dec. 2023 ($-222.81 Mil).

Immunome Retained Earnings Historical Data

The historical data trend for Immunome's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Retained Earnings Chart

Immunome Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-36.56

-54.39

-79.11

-116.00

-222.81

Immunome Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-130.17	-222.81	-352.30	-388.42	-435.52

Immunome Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Immunome (NAS:IMNM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Immunome Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011

Website

https://www.immunome.com

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Executives

Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Robert Lechleider	officer: Chief Medical Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett	officer: SVP Operations	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Jean Jacques Bienaime	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Higgins	officer: Chief Scientific Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas	director, other: See remarks	1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner	officer: Chief Strategy Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson	officer: Chief Technology Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp	director, 10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast	director
Michael Lefenfeld	director	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma	director, officer: President and CEO	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim	director	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019